{"id":"ras-inhibitors","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Cough (ACE inhibitors)"},{"rate":"2-5","effect":"Hyperkalemia"},{"rate":"5-10","effect":"Dizziness"},{"rate":"3-8","effect":"Fatigue"},{"rate":"0.1-0.5","effect":"Angioedema (rare)"}]},"_chembl":{"chemblId":"CHEMBL4303198","moleculeType":"Small molecule","molecularWeight":"405.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"RAS inhibitors work by interrupting the renin-angiotensin-aldosterone system (RAAS), which regulates blood pressure and fluid balance. By inhibiting angiotensin-converting enzyme (ACE inhibitors) or blocking angiotensin II receptors (ARBs), these drugs prevent vasoconstriction and aldosterone release, leading to vasodilation and reduced sodium retention. This results in lower blood pressure and reduced strain on the heart and kidneys.","oneSentence":"RAS inhibitors block the renin-angiotensin system to reduce blood pressure and protect organs from hypertension-related damage.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:03:53.969Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure"},{"name":"Chronic kidney disease"},{"name":"Post-myocardial infarction"}]},"trialDetails":[{"nctId":"NCT03244956","phase":"PHASE2","title":"Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2017-12-27","conditions":"Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation","enrollment":40},{"nctId":"NCT06445062","phase":"PHASE1, PHASE2","title":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2024-05-24","conditions":"Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma","enrollment":1130},{"nctId":"NCT06162221","phase":"PHASE1, PHASE2","title":"Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2024-01-18","conditions":"Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer","enrollment":616},{"nctId":"NCT07397338","phase":"PHASE1, PHASE2","title":"Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2026-01-30","conditions":"Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC)","enrollment":370},{"nctId":"NCT07391267","phase":"NA","title":"Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-01","conditions":"Chronic Kidney Diseases, MAFLD","enrollment":90},{"nctId":"NCT07201519","phase":"PHASE2","title":"Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy","status":"RECRUITING","sponsor":"Michael J Cavnar, MD","startDate":"2026-01-23","conditions":"Colorectal Cancer Metastatic, Intrahepatic Cholangiocarcinoma","enrollment":80},{"nctId":"NCT07325435","phase":"PHASE4","title":"Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists","status":"ACTIVE_NOT_RECRUITING","sponsor":"MaryAnn Banerji","startDate":"2024-12-21","conditions":"Type 2 Diabetes (T2DM)","enrollment":60},{"nctId":"NCT07314684","phase":"PHASE4","title":"GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM","status":"RECRUITING","sponsor":"Federico II University","startDate":"2025-09-08","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":80},{"nctId":"NCT04151342","phase":"","title":"CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2020-01-17","conditions":"Cancer, Malignancies Multiple, Malignant Solid Tumor","enrollment":5500},{"nctId":"NCT07257653","phase":"PHASE2","title":"The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2025-10-21","conditions":"Colorectal Neoplasms, RAS, BRAF","enrollment":70},{"nctId":"NCT03188887","phase":"PHASE3","title":"Treatment of IgA Nephropathy According to Renal Lesions","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-20","conditions":"IgA Nephropathy","enrollment":62},{"nctId":"NCT06862115","phase":"PHASE3","title":"The Effect of Discontinuation of Renin Angiotensin System Inhibitors on the Perioperative Myocardial Injury in Adult Patients Undergoing Colorectal Cancer Surgery","status":"RECRUITING","sponsor":"Kasr El Aini Hospital","startDate":"2025-03-01","conditions":"Myocardium; Injury, Perioperative/Postoperative Complications, Angiotensin-Converting-Enzyme Inhibitor","enrollment":156},{"nctId":"NCT04892017","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Deciphera Pharmaceuticals, LLC","startDate":"2021-06-15","conditions":"Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":144},{"nctId":"NCT02671435","phase":"PHASE1, PHASE2","title":"A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedImmune LLC","startDate":"2016-02-22","conditions":"Advanced Solid Tumors","enrollment":383},{"nctId":"NCT06962254","phase":"PHASE1","title":"Imatinib and Trametinib for KRAS-mutated Solid Tumor","status":"RECRUITING","sponsor":"China Medical University Hospital","startDate":"2025-05-10","conditions":"Solid Tumor Cancer","enrollment":10},{"nctId":"NCT04662723","phase":"PHASE4","title":"Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.","status":"RECRUITING","sponsor":"Fondazione Schena","startDate":"2023-05-01","conditions":"Glomerulonephritis, Immunoglobulin A Nephropathy","enrollment":878},{"nctId":"NCT06858384","phase":"NA","title":"RAK-PRIDE: Optimizing Proton Pump Inhibitor Use Through Education and Intervention","status":"RECRUITING","sponsor":"RAK Medical and Health Sciences University","startDate":"2025-03","conditions":"Proton Pump Inhibitors, Deprescribing, Inappropriate Use","enrollment":479},{"nctId":"NCT03563144","phase":"PHASE2","title":"QUILT-3.088: NANT Pancreatic Cancer Vaccine","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-08","conditions":"Metastatic Pancreatic Cancer","enrollment":""},{"nctId":"NCT03169738","phase":"PHASE1, PHASE2","title":"QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-02","conditions":"Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT06835179","phase":"PHASE2","title":"SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-02","conditions":"Unresectable Metastatic Colorectal Cancer, Microsatellite Stable (MSS) Colorectal Cancer (CRC), RAS-mutant Colorectal Cancer","enrollment":28},{"nctId":"NCT05709444","phase":"PHASE2","title":"A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease","status":"COMPLETED","sponsor":"Palatin Technologies, Inc","startDate":"2022-12-26","conditions":"Kidney Disease","enrollment":16},{"nctId":"NCT03418779","phase":"PHASE2, PHASE3","title":"Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2019-07-04","conditions":"IgA Nephropathy at High Risk of Developing ESRD","enrollment":60},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT03374449","phase":"NA","title":"Impact of Renin-Angiotensin System Inhibitors Continuation on Outcome After Major Surgery","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-06","conditions":"Renin Angiotensin System, Surgery","enrollment":2222},{"nctId":"NCT06425705","phase":"PHASE2","title":"Impact of Silymarin Adjunct Therapy on Proteinuria in Type 2 Diabetic Patients on RAS Inhibitors","status":"COMPLETED","sponsor":"Lahore General Hospital","startDate":"2022-02-25","conditions":"Type 2 Diabetes Mellitus","enrollment":70},{"nctId":"NCT06344247","phase":"NA","title":"Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2023-09-01","conditions":"Obesity, Chronic Kidney Diseases","enrollment":48},{"nctId":"NCT06321081","phase":"PHASE2","title":"ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC","status":"RECRUITING","sponsor":"Beijing Hospital","startDate":"2024-03-01","conditions":"RAS Mutation, Metastatic Colorectal Cancer, MSS","enrollment":60},{"nctId":"NCT06314997","phase":"PHASE2","title":"Dynamic Changes in Circulating Tumour Cells Protein Expression","status":"RECRUITING","sponsor":"Matteo's Friends","startDate":"2019-01-14","conditions":"Recurrence Free Survival","enrollment":150},{"nctId":"NCT04364984","phase":"","title":"ARB, ACEi, DRi Effects on COVID-19 Course Disease","status":"COMPLETED","sponsor":"Medical Practice Prof D. Ivanov","startDate":"2020-04-01","conditions":"Hypertension, COVID-19","enrollment":112},{"nctId":"NCT02278588","phase":"","title":"Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2014-11","conditions":"Parkinson's Disease","enrollment":45},{"nctId":"NCT04351581","phase":"NA","title":"Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With and Without COVID-19","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2020-05-18","conditions":"Covid-19","enrollment":78},{"nctId":"NCT04353596","phase":"PHASE4","title":"Stopping ACE-inhibitors in COVID-19","status":"COMPLETED","sponsor":"Medical University Innsbruck","startDate":"2020-04-20","conditions":"SARS-CoV-2, COVID-19","enrollment":216},{"nctId":"NCT05141552","phase":"NA","title":"The Safety of Dapagliflozin in Hemodialysis Patients With Heart Failure","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2022-01-03","conditions":"Hemodialysis Complication","enrollment":20},{"nctId":"NCT02176278","phase":"NA","title":"Using a Diabetic Kidney Disease (DKD) Registry to Treat to Multiple Targets (TMT)","status":"COMPLETED","sponsor":"Asia Diabetes Foundation","startDate":"2014-06","conditions":"Diabetic Kidney Disease","enrollment":2400},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT04238702","phase":"PHASE4","title":"Renohemodynamic Effects of Combined empagliflOzin and LosARtan","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2020-11-04","conditions":"Diabetes Mellitus, Type 2, Diabetic Kidney Disease","enrollment":24},{"nctId":"NCT05063058","phase":"NA","title":"Biomarker-driven Therapy for Melanoma","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2016-01","conditions":"Melanoma","enrollment":100},{"nctId":"NCT02510001","phase":"PHASE1","title":"MEK and MET Inhibition in Colorectal Cancer","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-11","conditions":"Solid Tumor, Colorectal Cancer","enrollment":82},{"nctId":"NCT04286399","phase":"PHASE4","title":"Asian Diabetes Outcomes Prevention Trial","status":"RECRUITING","sponsor":"National Heart Centre Singapore","startDate":"2019-07-01","conditions":"Diabetes Mellitus, Cardiovascular Diseases","enrollment":2400},{"nctId":"NCT04329195","phase":"PHASE3","title":"ACE Inhibitors or ARBs Discontinuation in Context of COVID-19 Pandemic","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-09","conditions":"History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection","enrollment":44},{"nctId":"NCT04351724","phase":"PHASE2, PHASE3","title":"Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2020-04-16","conditions":"COVID-19","enrollment":500},{"nctId":"NCT00985322","phase":"PHASE3","title":"Angiotensin-converting-enzyme (ACE) Inhibitors in Hemodialysis","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2009-05","conditions":"Left Ventricular Hypertrophy, Hypertension","enrollment":269},{"nctId":"NCT04572724","phase":"PHASE4","title":"The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value","status":"UNKNOWN","sponsor":"Shenzhen Second People's Hospital","startDate":"2020-07-06","conditions":"Peritoneal Dialysis Complication, Hemodialysis Complication, Heart Failure","enrollment":120},{"nctId":"NCT04524494","phase":"","title":"Human Intestinal Amino Acid Absorption and the Role of a Local RAS","status":"COMPLETED","sponsor":"University Children's Hospital Basel","startDate":"2010-01-27","conditions":"Renin-Angiotensin Aldosterone System (RAS)","enrollment":50},{"nctId":"NCT01287130","phase":"PHASE1","title":"AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-01-07","conditions":"Colonic Neoplasms, Cancer of the Colon, Colon Cancer","enrollment":10},{"nctId":"NCT03195023","phase":"PHASE4","title":"Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)","status":"UNKNOWN","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2015-06","conditions":"Renal Insufficiency, Chronic, Proteinuria","enrollment":106},{"nctId":"NCT01461499","phase":"PHASE4","title":"Shiga Microalbuminuria Reduction Trial-2","status":"COMPLETED","sponsor":"Shiga University","startDate":"2011-10","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":237},{"nctId":"NCT01454583","phase":"","title":"Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany","status":"COMPLETED","sponsor":"Stiftung Institut fuer Herzinfarktforschung","startDate":"2008-10","conditions":"Arterial Hypertension","enrollment":15337},{"nctId":"NCT01333475","phase":"PHASE2","title":"MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-03","conditions":"Colorectal Neoplasms","enrollment":21},{"nctId":"NCT01557140","phase":"PHASE4","title":"A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy","status":"COMPLETED","sponsor":"Federal University of Minas Gerais","startDate":"2003-05","conditions":"Chagas Cardiomyopathy, Heart Failure, Dilated Cardiomyopathy","enrollment":42},{"nctId":"NCT01195818","phase":"NA","title":"Albuminuria Reduction With Renin Angiotensin System Inhibitors in SCA Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2010-09","conditions":"Sickle Cell Disease","enrollment":53},{"nctId":"NCT00721773","phase":"NA","title":"Renal Protective Effects of Renin Angiotensin System (RAS) Inhibitor in Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2008-09","conditions":"Renal Function Disorder","enrollment":200},{"nctId":"NCT01771783","phase":"PHASE1","title":"RAS-Peptide-Profile Study in Healthy Male Subjects","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2012-11","conditions":"RAS Peptide Profile in Healthy Volunteers","enrollment":12},{"nctId":"NCT01252368","phase":"","title":"Human Intestinal Amino Acid Absorption and the Role of a Local (Renin)-Angiotensin System (RAS)","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2009-12","conditions":"Healthy Participants, Hypertension","enrollment":48},{"nctId":"NCT01198275","phase":"PHASE3","title":"n-3 Polyunsaturated Fatty Acids (PUFAs) in the Prevention of Atrial Fibrillation","status":"COMPLETED","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2006-01","conditions":"Atrial Fibrillation","enrollment":199},{"nctId":"NCT01115426","phase":"PHASE4","title":"Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis","status":"COMPLETED","sponsor":"University Magna Graecia","startDate":"1997-01","conditions":"IGA Glomerulonephritis","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":985,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"RAS Inhibitors","genericName":"RAS Inhibitors","companyName":"Shenzhen Second People's Hospital","companyId":"shenzhen-second-people-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RAS inhibitors block the renin-angiotensin system to reduce blood pressure and protect organs from hypertension-related damage. Used for Hypertension, Heart failure, Chronic kidney disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}